微肿瘤模型构建及其药敏检测技术中国专家共识(2023年版)  

Chinese experts consensus on the construction of patient-derived tumor-like cell cluster(PTC)model and anti-tumor drug sensitivity detection technology(2023 Version)

作　　者：中国生物医学工程学会类器官与器官芯片分会 中国医药生物技术协会基因检测技术分会 季加孚 席建忠[3] Organoids and Organ-on-a-Chip Branch of Chinese Society of Biomedical Engineering;China Medical Biotechnology Association Gene Testing Technology Branch

机构地区：[1]不详 [2]北京大学肿瘤医院 [3]北京大学未来技术学院

出　　处：《生物医学转化》2023年第4期86-94,共9页Biomedical transformation

基　　金：国家自然科学基金项目(82150005);北京协和医院中央高水平医院临床科研专项2022年专科提升计划项目(2022-PUMCH-B-005)。

摘　　要：患者来源类肿瘤细胞簇(Patient-DerivedTumor-LikeCellCluster,PTC)简称微肿瘤或微肿瘤PTC,是一种新型的原代3D肿瘤模型,该模型在病理组织学特征、分子遗传学特征方面保持了跟原始肿瘤组织的高度相似性。同时,该模型在培养过程中保留了原始肿瘤组织中的成纤维细胞和免疫细胞,从而高度还原了原始肿瘤组织微环境特征。微肿瘤PTC模型可广泛的应用于肿瘤基础科学研究、精准治疗和新药研发等领域。然而,由于微肿瘤PTC模型的构建及应用涉及到多种技术,流程多,影响因素多,目前,国内对微肿瘤PTC模型构建、鉴定、药敏检测等操作尚未建立规范标准。为此,特组织编写《微肿瘤模型构建及药敏检测技术中国专家共识(2023年版)》,以利于推动和指导微肿瘤PTC模型构建以及基于此模型药敏检测技术的应用。The patient-derived tumor-like cell cluster(PTC),also known as mini-tumor,represents a novel 3D tumor model with a high resemblance to the original tumor tissue in terms of histopathological and genetic characteristics.Notably,PTCs include stromal cells such as fibroblasts and various immune cells,effectively recapitulating the microenvironment of the original tumor tissue.With broad applications in basic scientific research,precision medicine,and drug discovery,the construction and utilization of PTCs involve intricate technical processes.However,the absence of a standardized procedure for PTC construction,identification,and drug sensitivity detection poses a challenge.Addressing this gap,we present the"Chinese expert consensus on the construction of patient-derived tumor-like cell cluster(PTC)model and anti-tumor drug sensitivity detection technology(2023 Version)."This consensus aims to enhance the comprehension of the PTC model and provide guidance for its application in anti-tumor drug sensitivity testing.

关 键 词：微肿瘤PTC 肿瘤 肿瘤药敏检测 共识 

分 类 号：R73-354[医药卫生—肿瘤]